SecBot SecBot
SECBOTREPLAY Home › Report › FHTX

FHTX · Foghorn Therapeutics reported Q2 2026 financial results with a net loss…

Foghorn Therapeutics Inc. · 8-K filed Aug 6, 2026 at 07:01 ET

At the news

MIXEDIMPACT 5/10

8-K filed Aug 6, 2026 at 07:01 ET

Foghorn Therapeutics reported Q2 2026 financial results with a net loss of $7.2M, significantly narrower than the $17.9M loss in Q2 2025, driven by a $14.2M cumulative catch-up adjustment in collaboration revenue from the Lilly agreement. The company highlighted its FHD-909 Phase 1 trial advancing as planned and a new immunology/inflammation program, but disclosed a delay in the CBPd-171 timeline due to a CRO operational issue. The narrower net loss is a positive, but the one-time revenue adjustment and the CBPd-171 delay temper the outlook for a pre-revenue biotech.

  • Net loss narrowed to $7.2M in Q2 2026 from $17.9M in Q2 2025, largely due to a $14.2M cumulative catch-up adjustment in collaboration revenue.
  • Collaboration revenue surged to $16.1M from $7.6M YoY, driven by the catch-up adjustment tied to the scheduled expiration of the Lilly research term in December 2026.
  • Cash, cash equivalents, and marketable securities stood at $167.6M, providing runway into the first half of 2028.
  • The CBPd-171 (FHT-171) timeline has been delayed due to an unexpected operational issue at a third-party CRO; updated guidance is pending.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access